• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Director Makker Gotham was granted 49,434 shares (SEC Form 4)

    7/18/25 4:05:40 PM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RCKT alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Makker Gotham

    (Last) (First) (Middle)
    C/O ROCKET PHARMACEUTICALS, INC.
    9 CEDARBROOK DRIVE

    (Street)
    CRANBURY NJ 08512

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    ROCKET PHARMACEUTICALS, INC. [ RCKT ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/18/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 06/18/2025 A(1) 30,000(1) A $0(1) 395,912 I By Simran Investment Group(2)
    Common Stock 06/18/2025 A(3) 19,434(3) A $0(1) 415,346 I By Simran Investment Group(2)
    Common Stock 621,500 I By Non-Revocable Trust(4)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2026.
    2. Represents RSUs issued to the Reporting Person in lieu of director retainer fees of $55,000. The RSUs will vest in full on June 18, 2026.
    3. The securities may be deemed beneficially owned by Gotham Makker, M.D., who serves as the Chief Executive Officer and Chief Investment Officer of Simran Investment Group and who is a director of the Issuer. Dr. Makker exercises voting and dispositive control over the securities held by Simran Investment Group and is therefore deemed be the beneficial owner of securities owned or controlled by Simran Investment Group. Notwithstanding the foregoing, Dr. Makker disclaims personal beneficial ownership of the reported securities held by Simran Investment Group, except to the extent of his pecuniary interest therein.
    4. The securities may be deemed to be beneficially owned by the reporting person and are held by a non-revocable trust for the benefit of the reporting person's children. The reporting person has no voting or investment power over all securities owned by the trust.
    /s/ Martin Wilson, as attorney-in-fact for Gotham Makker 07/18/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $RCKT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $RCKT

    DatePrice TargetRatingAnalyst
    7/25/2025$4.00Buy → Neutral
    BofA Securities
    5/30/2025$5.00Outperform → In-line
    Evercore ISI
    5/28/2025Overweight → Neutral
    Analyst
    5/28/2025$2.00Neutral → Sell
    Goldman
    5/28/2025$8.00Outperform → Market Perform
    Leerink Partners
    5/28/2025$2.50Buy → Hold
    Jefferies
    5/28/2025$7.00Overweight → Equal-Weight
    Morgan Stanley
    5/27/2025Buy → Hold
    TD Cowen
    More analyst ratings

    $RCKT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rocket Pharmaceuticals downgraded by BofA Securities with a new price target

      BofA Securities downgraded Rocket Pharmaceuticals from Buy to Neutral and set a new price target of $4.00

      7/25/25 9:00:02 AM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rocket Pharmaceuticals downgraded by Evercore ISI with a new price target

      Evercore ISI downgraded Rocket Pharmaceuticals from Outperform to In-line and set a new price target of $5.00

      5/30/25 10:04:19 AM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rocket Pharmaceuticals downgraded by Analyst

      Analyst downgraded Rocket Pharmaceuticals from Overweight to Neutral

      5/28/25 3:12:28 PM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCKT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rocket Pharmaceuticals Announces Strategic Corporate Reorganization and Pipeline Prioritization of Cardiovascular Programs

      Restructuring pipeline to focus on AAV cardiovascular platform (Danon disease, PKP2-ACM, BAG3-DCM) and regulatory activities for KRESLADI™ (severe LAD-I), setting foundation for near- and long-term value creation Organizational restructuring expected to reduce headcount by approximately 30% and lower 12-month cash burn by nearly 25% Company expects current cash runway to fund operations into the second quarter of 2027 Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced a strategic corporate reorganization and pipeline prioritizatio

      7/24/25 7:00:00 AM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy

      Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to RP-A601, the Company's investigational adeno-associated virus (AAV)-based gene therapy for the treatment of PKP2-arrhythmogenic cardiomyopathy (ACM), a life-threatening heart failure disease causing ventricular arrhythmias and sudden cardiac death. RMAT designation was granted based on positive safety and efficacy data from the Phase 1 RP-A601 clinical trial and will

      7/17/25 7:00:00 AM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy

      RP-A701 is a first-in-class gene therapy for the treatment of BAG3-associated dilated cardiomyopathy BAG3-associated dilated cardiomyopathy is a rare, inherited heart condition caused by mutations in the BAG3 gene, leading to early-onset, progressive heart failure due to impaired cardiac function, high morbidity, and premature mortality Rocket plans to conduct a Phase 1 trial in the U.S. and is working towards the first patient treatment Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that it has received clearance from the U.S

      6/30/25 7:00:00 AM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCKT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO Shah Gaurav bought $101,600 worth of shares (20,000 units at $5.08), increasing direct ownership by 3% to 792,680 units (SEC Form 4)

      4 - ROCKET PHARMACEUTICALS, INC. (0001281895) (Issuer)

      4/14/25 6:57:31 PM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Patel Kinnari bought $99,165 worth of shares (21,099 units at $4.70) (SEC Form 4)

      4 - ROCKET PHARMACEUTICALS, INC. (0001281895) (Issuer)

      4/10/25 4:07:53 PM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCKT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Pratumsuwan Piratip was granted 30,000 shares (SEC Form 4)

      4 - ROCKET PHARMACEUTICALS, INC. (0001281895) (Issuer)

      7/18/25 4:05:46 PM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Wong Roderick was granted 47,667 shares (SEC Form 4)

      4 - ROCKET PHARMACEUTICALS, INC. (0001281895) (Issuer)

      7/18/25 4:05:40 PM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Makker Gotham was granted 49,434 shares (SEC Form 4)

      4 - ROCKET PHARMACEUTICALS, INC. (0001281895) (Issuer)

      7/18/25 4:05:40 PM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCKT
    SEC Filings

    See more
    • Rocket Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - ROCKET PHARMACEUTICALS, INC. (0001281895) (Filer)

      7/24/25 7:10:15 AM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rocket Pharmaceuticals Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities

      8-K - ROCKET PHARMACEUTICALS, INC. (0001281895) (Filer)

      7/23/25 4:29:39 PM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rocket Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - ROCKET PHARMACEUTICALS, INC. (0001281895) (Filer)

      7/17/25 7:46:23 AM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCKT
    Leadership Updates

    Live Leadership Updates

    See more
    • NodThera Announces Appointment of Elisabeth Björk as Board Member

      NodThera Announces Appointment of Elisabeth Björk as Board Member Former SVP at AstraZeneca R&D brings deep expertise in obesity and cardiometabolic research, portfolio strategy development and commercializationAppointment follows commencement of Phase 2 RESOLVE-1 trial of oral NLRP3 inflammasome inhibitor NT-0796 in patients with obesity Philadelphia, PA, June 17, 2025 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces the appointment of Elisabeth Björk, M.D., Ph.D. as Board Member. Elisabeth has more than 20 years of experience in late-stage cl

      6/17/25 7:00:00 AM ET
      $PHVS
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress

      Enrollment completed in September and dosing ongoing in the Phase 2 pivotal study of RP-A501 for Danon disease Updated Phase 1 data from RP-A501 for Danon disease anticipated at American Heart Association's 2024 Late-Breaking Scientific Sessions Enrollment completed in low dose cohort of Phase 1 study of RP-A601 for PKP2-ACM; Preliminary data expected in the first half of 2025 Rolling BLA submission initiated for RP-L102 for Fanconi Anemia Progress on FDA-approval of KRESLADI for severe LAD-I; Approval anticipated in 2025 Appointed Mikael Dolsten, M.D., Ph.D., to Board of Directors Cash, cash equivalents and investments of approximately $235.7M; expected operational runway into 2026

      11/7/24 4:01:00 PM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors

      Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced the appointment of Mikael Dolsten, M.D., Ph.D., as an independent director to its Board of Directors. Dr. Dolsten is an accomplished industry executive with extensive global pharmaceutical management experience. "As an industry-leading pharmaceutical executive, I am very pleased to welcome Mikael to our Board of Directors," said Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharma. "His research and development experience will help advance our leading scientific capabilities and

      9/10/24 7:00:00 AM ET
      $PFE
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCKT
    Financials

    Live finance-specific insights

    See more
    • Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease

      Conference call to be held later today at 8:30 a.m. ET Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, late-stage biotechnology company advancing an integrated pipeline of genetic therapies for rare diseases, today announced an update related to RP-A501, its investigational gene therapy for Danon disease. A patient participating in the Phase 2 pivotal trial of RP-A501 experienced an unexpected Serious Adverse Event (SAE). The SAE involved clinical complications related to a capillary leak syndrome. Rocket is conducting a comprehensive root cause analysis and remains in active dialogue with the U.S. Food and Drug Administration (FDA) and other key stakeholders, with the c

      5/27/25 7:00:00 AM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rocket Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Progress

      — Reported positive safety data at ASGCT from pediatric cohort of Phase 1 Danon Disease study that demonstrated RP-A501 was well-tolerated; efficacy update across pediatric as well as adult cohorts on track for late Q3 2022— — Announced top-line data at ASGCT from pivotal Phase 2 trial for severe LAD-I that showed RP-L201 was well-tolerated with 100% overall survival at one year; regulatory filings anticipated in first half of 2023 — — Primary endpoint met for Fanconi Anemia pivotal Phase 2 trial, FDA dialogue initiated for BLA planning; continued data readouts for Fanconi Anemia and Pyruvate Kinase Deficiency programs expected in Q4 2022 — — Achieved Current Good Manufacturing Practice

      8/8/22 4:01:00 PM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rocket Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Progress

      — Continued to advance clinical gene therapy programs for the treatment of Danon Disease, Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I) and Pyruvate Kinase Deficiency (PKD) — — Updates on all four programs to be presented at the 2022 Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) this month; trials on track for 2022 data readouts — — Appointed internationally recognized cardiovascular physician-scientist and biopharmaceutical executive Fady Malik, M.D., Ph.D., to Board of Directors – — Named experienced commercial leader Carlos Martin to Chief Commercial Officer and proven biotech executive Jessie Yeung to Vice President of Investor Relations and C

      5/5/22 4:01:00 PM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCKT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Rocket Pharmaceuticals Inc.

      SC 13D/A - ROCKET PHARMACEUTICALS, INC. (0001281895) (Subject)

      12/16/24 7:51:51 PM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Rocket Pharmaceuticals Inc.

      SC 13G/A - ROCKET PHARMACEUTICALS, INC. (0001281895) (Subject)

      11/8/24 10:52:38 AM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Rocket Pharmaceuticals Inc. (Amendment)

      SC 13G/A - ROCKET PHARMACEUTICALS, INC. (0001281895) (Subject)

      4/5/24 9:47:13 AM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care